Science news, opinion, interviews and product reports for scientists across all disciplines. Make Scientist Live my homepage  SciLive on Twitter7th November 2009

BookMark


Search

 

Readers Poll


Yes
No
Undecided


View Results »

Subscribe

Subscribe to Scientist Live

Click here for FREE subscription to eLab and eFood magazines

 

Newsletter

RSS Feed

Get the Scientist Live RSS Feed
RSS Feed

Visit our Products and Services Section


ITCM is a global manufacturer and leading innovator in customised machinery and systems for pharmaceutical packaging and processing.
eLab 2009-5-15 Issue

 View online magazine
 
 


eFood 2009-10-01 Issue

 View online magazine
 

eLab - Medical

HIV-1 infected macrophage-specific anti-viral therapy

Pauline Chugh, Birgit Bradel-Tretheway, Carlos M.R. Monteiro-Filho, Vicente Planelles, Sanjay B Maggirwar email, Stephen Dewhurst and Baek Kim

Retrovirology 2008, 5:11doi:10.1186/1742-4690-5-11Background

ABSTRACT (Provisional) 

Unlike CD4+ T cells, HIV-1 infected macrophages exhibit extended life span even upon stress, consistent with their in vivo role as long-lived HIV-1 reservoirs. Results: Here, we demonstrate that PI3K/Akt inhibitors, including clinically available Miltefosine, dramatically reduced HIV-1 production from long-living virus-infected macrophages. These PI3K/Akt inhibitors hyper-sensitize infected macrophages to extracellular stresses that they are normally exposed to, and eventually leads to cell death of infected macrophages without harming uninfected cells. Based on the data from these Akt inhibitors, we were able to further investigate how HIV-1 infection utilizes the PI3K/Akt pathway to establish the cytoprotective effect of HIV-1 infection, which extends the lifespan of infected macrophages, a key viral reservoir. First, we found that HIV-1 infection activates the well characterized pro-survival PI3K/Akt pathway in primary human macrophages, as reflected by decreased PTEN protein expression and increased Akt kinase activity. Interestingly, the expression of HIV-1 or SIV Tat is sufficient to mediate this cytoprotective effect, which is dependent on the basic domain of Tat - a region that has previously been shown to bind p53. Next, we observed that this interaction appears to contribute to the downregulation of PTEN expression, since HIV-1 Tat was found to compete with PTEN for p53 binding; this is known to result in p53 destabilization, with a consequent reduction in PTEN protein production. Conclusions: Since HIV-1 infected macrophages display highly elevated Akt activity, our results collectively show that PI3K/Akt inhibitors may be a novel therapy for interfering with the establishment of long-living HIV-1 infected reservoirs.

 Originally published in BioMed Central. Click here for pdf version of report.

 

©2008 Setform Limited

Site By OWB